Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Overland Park, Kansas 66212


Purpose:

The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.


Study summary:

A Phase 1, single-center, randomized, double-blind, double-dummy drug interaction study.


Criteria:

Inclusion Criteria: - Healthy adult males and females, 18 to 55 years of age - Body Mass Index (BMI) ≥19 and ≤30 kg/m2 (for both males and females) Exclusion Criteria: - History or presence of significant disease - History of substance abuse or dependence (except caffeine), or treatment for substance use disorder(s) within the year prior to screening or within 6 months for nicotine including e-cigarettes - Use of any tobacco-containing or nicotine-containing products within 6 months prior to the first dose - Use of any prescription or the over-the-counter medications within 14 days


NCT ID:

NCT02402595


Primary Contact:

Principal Investigator
Martin Kankam, MD, PhD, MPH
Vince and Associates Clinical Research Inc.


Backup Contact:

N/A


Location Contact:

Overland Park, Kansas 66212
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.